SIETES :: 92426 citas

Resultados de la búsqueda por ANTIBIÓTICOS (2) REFINAR BÚSQUEDA

1.

Anónimo. FDA mandates new warnings for fluoroquinolones concerning mental health and low blood sugar. DIA Daily 2018:1. [Ref.ID 102712]

2.

Silverman E. STAT Plus: Novartis is the latest big drug maker to exit antibiotic research. STAT Daily Recap 2018:3. [Ref.ID 102708]

3.

Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]

4.

Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]

5.

Chen TT, Yeh YC, Chien KL, Lai MS, Tu YK. Risk of infective endocarditis after invasive dental treatments: a case-only study. Circulation 2018:19 de abril. [Ref.ID 102607]

6.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

7.

Mitjà O, Godornes C, Houinei W, Kapa A, Paru R, Abel H, González-Beiras C, Bieb SV, Wangi J, Barry AE, Sanz S, Bassat Q, Lukehart SA. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet 2018;391:21 de abril. [Ref.ID 102568]

8.

Šmajs D, Pospíšilová P. Macrolide resistance in yaws. Lancet 2018;391:21 de abril. [Ref.ID 102567]

9.

Anónimo. Clarithromycin (Biaxin): Drug safety communication - Potential increased risk of heart problems or death in patients with heart disease. FDA U.S. Food and Drug Administration 2018:22 de febrero. [Ref.ID 102539]

10.

King LM, Sanchez GV, Bartoces M, Hicks A, Fleming-Dutra KE. Antibiotic Therapy Duration in US Adults With Sinusitis. JAMA Intern Med 2018:26 de marzo. [Ref.ID 102480]

11.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

12.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

13.

Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 2017;358:j4307. [Ref.ID 102094]

14.

Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]

15.

Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 2017;318:626-36. [Ref.ID 102056]

16.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

17.

Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]

18.

Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017;167:152-8. [Ref.ID 101991]

19.

Sing CW, Wong ICK, Cheung BMY, Chan JCY, Chu JKP, Cheung C-L. Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case–control study. Pharmacoepidemiol Drug Saf 2017;26:248-55. [Ref.ID 101954]

20.

Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S, the French National Network of Pharmacovigilance Centres. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017;83:1341-9. [Ref.ID 101945]